KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 59.93M | 13.69M | 1.43M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.93M | 13.69M | 1.43M | -- | -- |
| Cost of Revenue | 12.24M | 13.23M | 15.75M | 15.89M | 12.59M |
| Gross Profit | 47.69M | 467.00K | -14.33M | -15.89M | -12.59M |
| SG&A Expenses | 60.40M | 46.52M | 44.68M | 39.14M | 30.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.64M | 59.74M | 60.44M | 55.03M | 42.94M |
| Operating Income | -12.72M | -46.05M | -59.01M | -55.03M | -42.94M |
| Income Before Tax | -12.47M | -47.33M | -57.94M | -53.08M | -44.26M |
| Income Tax Expenses | -7.10M | 2.16M | 2.16M | -855.00K | 4.25M |
| Earnings from Continuing Operations | -5.37M | -49.48M | -60.10M | -52.23M | -48.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.37M | -49.48M | -60.10M | -52.23M | -48.51M |
| EBIT | -12.72M | -46.05M | -59.01M | -55.03M | -42.94M |
| EBITDA | -12.13M | -45.76M | -58.76M | -54.77M | -42.71M |
| EPS Basic | -0.10 | -0.92 | -1.12 | -0.98 | -0.92 |
| Normalized Basic EPS | -0.14 | -0.56 | -0.68 | -0.63 | -0.53 |
| EPS Diluted | -0.10 | -0.92 | -1.12 | -0.98 | -0.92 |
| Normalized Diluted EPS | -0.14 | -0.56 | -0.68 | -0.63 | -0.53 |
| Average Basic Shares Outstanding | 55.19M | 53.88M | 53.50M | 53.04M | 52.64M |
| Average Diluted Shares Outstanding | 55.19M | 53.88M | 53.50M | 53.04M | 52.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |